<DOC>
	<DOCNO>NCT00973817</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy use ELAD patient diagnose Acute On Chronic Hepatitis , include Acute Alcoholic Hepatitis .</brief_summary>
	<brief_title>Efficacy Safety Extracorporeal Liver Assist Device ( ELAD ) Acute Chronic Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<criteria>Age &gt; /= 18 &lt; /= 67 year ; AND Acute decompensation chronic liver disease precede 30 day ; AND MELD score 18 35 , inclusive ; AND Subject designate representative must provide Informed Consent Platelets &lt; 50,000mm baseline ; OR Evidence chronic renal failure define serum creatinine &gt; /= 2.5mg/dL measure 16 month period prior study entry . ( Subject exclude creatinine &gt; 2.5 mg/dL deem type1 hepatorenal syndrome ) ; OR Contraindication renal replacement therapy ( hemodialysis hemofiltration ) ; OR International Normalization Ratio ( INR ) &gt; 3.5 ; OR Septic shock define positive blood culture two following : Systolic blood pressure &lt; 90mmHg OR mean arterial pressure &lt; 60mmHg ; Tachypnea &gt; 20 breath per minute OR PaCO2 &lt; 32 mmHg ; White blood cell count &lt; 4000 cell/mm3 OR &gt; 12000 cell/mm3 ( &lt; 4 x 10 ( 9 ) &gt; 12 x 10 ( 9 ) cells/L ) . Evidence major hemorrhage indicate : require &gt; /= 4 unit pack red blood cell within 48 hour period prior Screening , OR hemodynamic instability ( sustain pulse &gt; 120 beats/min AND systolic blood pressure &lt; 100 mmHg one hour ) Subjects recent history gastrointestinal hemorrhage successfully treat remain hemodynamically stable period 48 hour eligible study investigator determines subject low risk rebleeding ; OR Evidence ( physical exam , history lab evaluation ) significant concomitant disease include chronic congestive heart failure , vascular disease , emphysema , AIDS , hepatitis due herpes virus , Wilson 's disease , BuddChiari syndrome ; OR Known history hepatocellular carcinoma beyond Milan criterion and/or portal vein thrombosis ; OR Evidence spontaneous bacterial peritonitis uncontrolled infection ; OR Evidence brain death determine blood flow study positive herniation AND/OR absence pupillary reflex ; OR Systolic blood pressure &lt; 85 mmHg OR MAP &lt; 50mmHg baseline ; OR Requirement escalate dos vasopressor support OR alphaadrenergic agent one hour long AND evidence hemodynamic instability ; OR Subject maximum vasopressor dose Screen ; OR Clinical radiographic evidence new stroke intracerebral bleeding ; OR Seizures uncontrolled medication ; OR Acute myocardial infarction base clinical and/or electrocardiographic evidence ; OR Lung disease define PaO2 &lt; 60mmHg room air , acute respiratory distress syndrome , history severe COPD interstitial lung disease ; OR Pregnancy determine betaHCG result lactation ; OR Participation another investigational drug , biologic , device study within 1 month enrollment . Subjects enrol observational study eligible trial . Previous liver transplant . Previous participation clinical trial involve ELAD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>AOCH</keyword>
</DOC>